Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: II

79 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Ahdoot, Michael	A031701	A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations, (IRB#839)
Anand, Neel	KUR-113/01	A proSpecTive, Randomized, controlled, single-blind, dose-finding, mUlti-Center, parallel group study of the safeTy and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft for the treatment of patients undergoing single-level transforaminal lumbar intErbody fusion (the STRUCTURE study)
Ayoub, Walid	VLX-301	A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Bairey-Merz, Noel	CLBS16-P02	A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CLBS16 DELIVERY BY INTRACORONARY OR RETROGRADE CORONARY SINUS ADMINISTRATION IN SUBJECTS WITH CORONARY MICROVASCULAR DYSFUNCTION AND WITHOUT OBSTRUCTIVE CORONARY ARTERY DISEASE (PHASE 2)
Basho, Reva	EIIT2020-BASHO-DARE	EIIT2020-BASHO-DARE: A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, Estrogen Receptor Positive, HER2 Negative Breast Cancer (IRB#1218)
Burford, Matthew	APL2-ALS-206	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Burwick, Richard	IIT-BURWICK2019	Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study
Chen, Peter	J2W-MC-PYAB	PYAB: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants with Mild to Moderate COVID-19 Illness
Chiu, Vi K.	DEK-DKK1-P205	DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) (IRB#782)
Chung, Alice	IIT2015-06-CHUNG-SNBO	Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65 (IRB#41396)
D'Agnolo, Alessandro	IIT2020-14-DAGNOLO-HIFU	IIT2020-14-DAGNOLO-HIFU High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy (IRB#832)
Figlin, Robert	PT2977-201	PT2977-201: A Phase 2 Trial of PT2977 In Combination With Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (IRB#54237)
Freedland, Stephen	IIT2018-06-FREEDLAND-AS3	IIT2018-06-FREEDLAND-AS3 (CAPS3): Carbohydrate and Prostate Study 3: Carbohydrate restricted diet intervention for men on prostate cancer active surveillance (IRB#53710)
Freedland, Stephen	IIT2018-23-FREEDLAND-POWR	IIT2018-23-Freedland-POWR: WALNUTS for POWER: Polyphenols, Omega-3 fatty acids, Weight loss, and EneRgy (IRB#55792)
Gangi, Alexandra	EA2197	EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial (IRB#01464)
Gong, Jun	ACCRU-GI-1623	ACCRU-GI-1623: (PULSE) A Randomized, Phase II Open-Label Study of Panitumumab Rechallenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (IRB#802)
Goodman, Marc	IIT2016-14-GOODMAN-NWUHCC	Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer (IRB#47043)
Hamid, Omid	CLXH254C12201	CLXH254C12201: A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma (IRB#0975)
Hamid, Omid	EIIT2020-HAMID-S19-00008	S19-00008: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma (IRB #390)
Hamid, Omid	SGNS40-002	SEA-CD40: An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies (IRB#1543)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hendifar, Andrew	ACCRU-GI-1907	ACCRU-GI-1907 (BrafPanc): A Phase II Trial of Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAF V600E Mutation (IRB#858)
Hendifar, Andrew	IIT2018-29-HENDIFAR-PNCX3	IIT2018-29-Hendifar-PNCX3: PANCREATIC-ENZYME REPLACEMENT THERAPY WITH PANCREAZE (PANCRELIPASE) DELAYED-RELEASE IN ADDITION TO STANDARD OF CARE FOR BORDERLINE RESECTABLE, LOCALLY ADVANCED, ADVANCED, AND UNRESECTABLE PANCREATIC ADENOCARCINOMA PATIENTS (PANCAX-3) WITH CACHEXIA AND EXOCRINE PANCREATIC INSUFFICIENCY (IRB#208)
Hendifar, Andrew	IIT2020-11-HENDIFAR-TELAT	IIT2020-11-Hendifar-TELAT: A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination with Keytruda in Subjects with Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (IRB#1157)
Hendifar, Andrew	MK-3475-158	MK-3475-158-00: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) (IRB#43687)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Hendifar, Andrew	MK6482-015	MK6482-015: A Study of MK-6482 Monotherapy in Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumors (pNET) (IRB#1491)
Hu, Jethro	GCAR-7213	GCAR-7213: GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) (IRB#52)
Jordan, Stanley	16-HMEDIDES-12	A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
Jordan, Stanley	CLAZACOVID19	A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 monoclonal) compared to placebo for the treatment of COVID-19 infection
Jordan, Stanley	MAU868-201	A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Kamrava, Mitchell	GTI-4711-201	GTI-4711-201 (GRECO-2): A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer (IRB#1197)
Labadzhyan, Artak	ISIS766720-CS5	An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients with Acromegaly
Lo, Simon	NANOPAC-2016-05	NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB#49989)
Majlessipour, Fataneh	APEC1621B	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations (IRB#57477)
Majlessipour, Fataneh	APEC1621MASTER-APEC1621SC	APEC1621MASTER-APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master and Screening Protocol (IRB#57413)
Makkar, Rajendra	2018-19	The ENCIRCLE High-Risk Trial SAPIEN M3 System TransCatheter MItral Valve ReplaCement via TransseptaL AccEss
Mehmi, Inderjit	EA6191	EA6191: The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma (IRB#1406)
Mehmi, Inderjit	EA6192	EA6192: A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) (IRB#1205)
Mehmi, Inderjit	SGN35-033	SGN35-033: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (IRB#1070)
Melmed, Gil	TAK-018-2001	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Merin, Noah	A041701	A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (IRB#1108)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Alain	P1719-SUR-Z11	P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155)
Mita, Monica	IIT2018-01-MCARTHUR-IPI	IIT2018-01-McArthur-IPI: A Single Arm Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (IRB#52157)
Moser, Franklin	20241	20241: Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions referred for contrast-enhanced MRI of the CNS (IRB#430)
Natale, Ronald	D6186C00001	D6186C00001:A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD) (IRB#97)
Natale, Ronald	ML41591	ML41591: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib plus Cobimetinib in Patients With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, Or BRAF V600E Molecular Alterations (IRB#715)
Noureddin, Mazen	AK-US-001-0102	A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN NON-CIRRHOTIC SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
Noureddin, Mazen	C2541013	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3
Noureddin, Mazen	GT-031-NASH-RX	A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Noureddin, Mazen	VK2809-202	VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG PHASE IN SUBJECTS WITH BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS
Osipov, Arsen	EIIT2020-OSIPOV-PEMDEF	EIIT2020-Osipov-PemDef/J18140: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC) (IRB#1038)
Padda, Sukhmani	S1900E	S1900E: A PHASE II STUDY OF AMG 510 IN PARTICIPANTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (IRB#01520)
Rader, Florian	CY6021	A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
Rader, Florian	MYK-461-019	AN EXPLORATORY, OPEN-LABEL, PROOF-OF-CONCEPT, PHASE 2A STUDY OF MAVACAMTEN (MYK-461) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP
Reckamp, Karen	CX-839-014	CX-839-014: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) (IRB#838)
Reckamp, Karen	ELVCAP-001-01	ELVCAP-001-01: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (IRB#862)
Reckamp, Karen	GO42501	GO42501: A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Neoadjuvant and Adjuvant Tiragolumab plus Atezolizumab,with or without Platinum-Based Chemotherapy, in Patients with Previously Untreated Locally Advanced Resectable Stage II, IIIA. or Select IIIB Non-Small Cell Lung Cancer (IRB#1128)
Reckamp, Karen	S1929	S1929: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) (IRB#1178)
Reckamp, Karen	U31402-A-U201	U31402-A-U201 (HERTHENA-Lung01): A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402)in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (IRB#942)
Rimel, Bobbie Jo	213409	GSK 213409: An Open-Label, Multicenter, Long-Term Treatment Extension Study in Subjects Who Have Completed a Prior 213409 Glaxosmithkline/Tesaro-Sponsored Niraparib Study and are Judged by the Investigator to Benefit from Continued Treatment with Niraparib (IRB#1281)
Rimel, Bobbie Jo	BBI-DSP7888-102CI	BBI-DSP7888-102CI: A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors (IRB#753)
Rimel, Bobbie Jo	D601HC00002	D601HC00002: A Phase 2b,Open-label,Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertibas Treatment for Recurrent or Persistent Uterine Serous Carcinoma(ADAGIO) (IRB#1082)
Rokhsar, Sepehr	ME-401-003	ME-401-003: A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies (IRB#509)
Rudnick, Jeremy	NRG-BN007	NRG-BN007: A Randomized Phase II/III Open-Label Study Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT Unmethlyated Glioblastoma (IRB#1075)
Spiegel, Brennan	IIT2021-05-SPIEGEL-VR	IIT2021-05-SPIEGEL-VR: Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (IRB#1363)
Sundaram, Vinay	DUR-C928-011	A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis
TEST, STAFF3	TEST3	TEST3: Faux study 3 for testing
Tagliati, Michele	TAK-071-2002	A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Tapson, Victor	20-0006	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Tapson, Victor	MK-4482-001	A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adultswith COVID-19
Wentzel, Kristopher	8951-CL-0103	A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression. (IRB#52384)
Yang, Ju Dong	IIT2020-01-YANG-G1001	IIT2020-01-YANG-G1001:Case-Control Study of the Glycotest HCC Panel vs AFP for the Detection of Early-Stage Hepatocellular Carcinoma (IRB#399)
Yu, John	IIT2020-09-YU-BBIST001	IIT2020-09-Yu-BBIST001: A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged with the Canvas System (IRB#1236)
Zaman, Tanzira	PLN-74809-IPF-202	A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF)
Zumsteg, Zachary	IIT2019-20-ZUMSTEG-HPVOPC	IIT2019-20-ZUMSTEG-HPVOPC: Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer (IRB#900)
Zumsteg, Zachary	NRG-HN005	NRG-HN005: A RANDOMIZED PHASE II/III TRIAL OF DE-INTENSIFIED RADIATION THERAPY FOR PATIENTS WITH EARLY-STAGE, P16-POSITIVE, NON-SMOKING ASSOCIATED OROPHARYNGEAL CANCER (IRB#189)
Zumsteg, Zachary	RTOG-1216	RTOG-1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck (IRB#1160)